Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT05989139

HF vs NIV in Acute Cardiogenic Pulmonary Edema

Led by Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Updated on 2025-08-15

30

Participants Needed

1

Research Sites

169 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The study's primary aim is * to compare the effects of two different ventilation modalities, non-invasive positive-pressure ventilation (NPPV) and high-flow nasal cannulae (HFNC), in the acute cardiogenic pulmonary edema (ACPE) setting, in terms of echocardiographic parameters of RV systolic and RV strain. * to determine the differences of the two interventions on other hemodynamic parameters echocardiographically assessed. * to assess the differences between the two interventions on physiological parameters, i.e., mean arterial pressure (MAP), heart rate (HR), respiratory rate (RR), oxygen saturation (SpO2), and on arterial blood gases (ABG) analysis parameters (i.e. relief of dyspnea and respiratory distress, patient comfort). Enrolled patients will receive NPPV and HFNC oxygen therapy in a randomized, cross-over fashion, for 40 minutes each (time 0, T0 and time 1, T1), followed by clinical and echocardiographic evaluation

CONDITIONS

Official Title

HF vs NIV in Acute Cardiogenic Pulmonary Edema

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age ≥ 18 y.o.;
  • Clinical diagnosis of ACPE in the setting of either AMI, acute myocarditis, acute/chronic severe mitral/aortic valve regurgitation, severe mitral/aortic stenosis, acute/chronic HF with rLVEF diagnosed according to European Society of Cardiology (ESC) guidelines [4];
  • Hypertensive crisis with systolic blood pressure >200 mmHg;
  • Other congenital or acquired structural heart disease causing post capillary pulmonary hypertension or combination of the previous.
  • Written informed consent.
Not Eligible

You will not qualify if you...

  • Age <18 y.o.;
  • Hypercapnia with respiratory acidosis (PaCO2 > 45 mmHg with pH < 7.35);
  • History of fever in the previous 4 days;
  • White blood cell count > 12.000;
  • Increased procalcitonin serum levels;
  • Consolidative areas at chest radiograph;
  • Hypotension (systolic blood pressure < 85 mmHg);
  • Cardiogenic shock;
  • Right ventricular (RV) dysfunction;
  • Previous cardiac surgery,
  • Glasgow Coma Scale score ≤ 8 points;
  • Impaired ability to protect the airway from aspiration;
  • Orotracheal intubation needed due to cardiopulmonary resuscitation maneuvers;
  • Respiratory arrest;
  • Severe hemodynamic instability;
  • Facial trauma, burns, recent facial surgery or facial anatomy which prevents from the application of the NPPV interface to patient's face.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Fondazione IRCCS Policlinico Agostino Gemelli Roma

Roma, Italy, 00168

Actively Recruiting

Loading map...

Research Team

T

Tommaso Sanna

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

CROSSOVER

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

HF vs NIV in Acute Cardiogenic Pulmonary Edema | DecenTrialz